Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Graceway Pharmaceuticals, LLC |
---|---|
Information provided by: | Graceway Pharmaceuticals, LLC |
ClinicalTrials.gov Identifier: | NCT00116675 |
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.
A second purpose is to evaluate the safety of the drug.
Condition | Intervention | Phase |
---|---|---|
Warts |
Drug: Resiquimod |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Single Blind, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects |
Ages Eligible for Study: | 3 Years to 11 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |
Children's Clinic of Jonesboro, PA | |
Jonesboro, Arkansas, United States, 72401 | |
United States, California | |
University of California - San Francisco | |
San Francisco, California, United States, 94143 | |
United States, Colorado | |
Longmont Clinic/Longmont Medical Research Network | |
Longmont, Colorado, United States, 80501 | |
United States, Missouri | |
Mercy Health Research | |
St. Louis, Missouri, United States, 63141 | |
United States, New Hampshire | |
Dartmouth-Hitchcock Medical Center | |
Lebanon, New Hampshire, United States, 03756 | |
United States, Rhode Island | |
Rhode Island Hospital - Jane Brown Building | |
Providence, Rhode Island, United States, 02903 | |
United States, Texas | |
DermResearch, Inc. | |
Austin, Texas, United States, 78759 | |
United States, Utah | |
Alpine Pediatrics | |
Pleasant Grove, Utah, United States, 84062 | |
United States, Washington | |
Walla Walla Clinic | |
Walla Walla, Washington, United States, 99362 | |
United States, Wisconsin | |
Advanced Healthcare | |
Milwaukee, Wisconsin, United States, 53209 |
Study ID Numbers: | 1535-RESI |
Study First Received: | June 30, 2005 |
Last Updated: | February 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00116675 |
Health Authority: | United States: Food and Drug Administration |
Common Wart(s) Pediatric Wart(s) |
Children 3M Pharmaceuticals Resiquimod |
Virus Diseases Skin Diseases, Infectious Warts |
Skin Diseases DNA Virus Infections Papillomavirus Infections |
Skin Diseases, Viral Neoplasms Tumor Virus Infections |